AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
FDA Weighs Safety Standards for Psychedelic Therapies 
Costco Revenue Beats Estimates as Inflation Drives Bulk Shopping 
BlackBerry Shares Rise as Q2 Earnings, Revenue Beat Estimates 
Novo Nordisk Strikes €1.17 Billion Nanexa Drug Delivery Deal 
Mexico-US Trade Talks Delayed to October as Tariff Negotiations Continue 
Japan Private-Sector Growth Slows as Domestic Demand Weakens 
NASA Resumes Cygnus XL Cargo Docking with Space Station After Software Fix 
Blue Origin New Glenn Explosion Could Delay Launch Operations Until 2028 
OpenAI Agent Breaches Australia Medicare Data Portal 
Asian Currencies Mixed as Dollar Holds Near Two-Month High 
Fed Unveils Stablecoin Rules Under GENIUS Act 
Trump Signs Order to Cut Routine Childhood Vaccines 
Akamai Shares Surge on $11.6B Anthropic AI Cloud Deal 
Add as a preferred source on Google
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
